OSE Immunotherapeutics SA

EPA:OSE.PA

6.05 (EUR) • At close June 5, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) EUR.

2024 Q42024 Q22023 Q42023 Q22022 Q42022 Q22021 Q42021 Q22020 Q42020 Q22019 Q42019 Q22018 Q42018 Q22017 Q42017 Q22016 Q42016 Q22015 Q42015 Q22014 Q42014 Q22013 Q42013 Q22012 Q42012 Q2
Revenue 0.83169.0460.8691.3582.25516.04717.3318.9754.5695.8499.97315.9793.84820.6083.8332.8490.3440.0390.0030.001000000
Cost of Revenue 0.8310000000-0.00100000000000000000
Gross Profit 069.0460.8691.3582.25516.04717.3318.9754.575.8499.97315.9793.84820.6083.8332.8490.3440.0390.0030.001000000
Gross Profit Ratio 01111111111111111111000000
Reseach & Development Expenses 18.28216.06517.20114.42713.50516.49616.83117.14513.2689.08713.49111.69.0610.639.029.5472.685.3511.9151.0241.7460.3870.0750.0790.6550.655
General & Administrative Expenses 2.16302.3883.5742.833.7645.1373.3664.70101.7142.1411.7571.6643.14601.8970.8760.7270.5910.5320.1310.0470.0430.0680.068
Selling & Marketing Expenses 00-2.2830.7321.3710.8360.6352.468-1.48301.0010.5840.4350.542-0.7900.2740.4050.5141.34300.1350.003000
SG&A 3.895.192.864.3064.2014.65.7725.8343.2183.8482.7152.7252.1922.2062.3562.2952.1711.2811.2411.9340.5320.2660.0530.0430.0680.068
Other Expenses -1.639000-0.029-0.049-0.058-0.0470000-2.021-2.458-2.253-1.6570.1750-0.5330-0.1170.0010000
Operating Expenses 20.45121.25512.32518.73317.30621.14522.37623.02616.48612.93516.20614.3259.21110.3879.12310.1735.1015.812.6692.9222.1820.6550.1270.1230.7230.723
Operating Income -19.58646.127-9.482-13.504-17.254-6.768-7.078-14.895-11.917-7.086-6.4951.434-5.5110.357-5.289-7.336-4.7914.224-2.621-2.799-2.161-0.654-0.128-0.122-0.722-0.722
Operating Income Ratio -23.5690.668-10.911-9.944-7.651-0.422-0.408-1.66-2.608-1.211-0.6510.09-1.4320.503-1.38-2.575-13.927108.308-873.667-2,799000000
Total Other Income Expenses Net -1.263-2.606-1.7961.56-1.032-1.741-0.4080.4-0.121-0.122-0.060.2970.133-0.24-0.109-0.0060.0528.108-0.01-0.143-0.017-0.0010.001-0.0010.0050.005
Income Before Tax -20.88357.108-11.278-14.391-18.286-5.168-7.063-14.495-12.038-7.208-6.2541.731-5.37710.084-5.399-7.342-4.74122.333-2.631-2.942-2.178-0.655-0.127-0.123-0.718-0.718
Income Before Tax Ratio -25.130.827-12.978-10.597-8.109-0.322-0.408-1.615-2.635-1.232-0.6270.108-1.3970.489-1.409-2.577-13.782572.641-877-2,942000000
Income Tax Expense -1.153-0.0670.135-2.532-2.505-3.189-1.701-3.0071.402-4.094-1.0881.2171.991.2071.2361.0020.9012.1730.01100.002-0.0010.001-0.0010.8720.872
Net Income -19.7357.175-11.143-11.86-15.781-1.979-5.362-11.488-13.441-3.114-5.1660.514-3.3878.877-4.163-6.34-3.8424.506-2.642-2.942-2.18-0.655-0.127-0.123-0.718-0.718
Net Income Ratio -23.7420.828-12.823-8.733-6.998-0.123-0.309-1.28-2.942-0.532-0.5180.032-0.880.431-1.086-2.225-11.163628.359-880.667-2,942000000
EPS -0.912.63-0.54-0.64-0.86-0.11-0.29-0.64-0.84-0.21-0.350.035-0.230.57-0.29-0.44-0.252.1-0.27-0.32-0.27-0.09-0.017-0.02-0.09-0.09
EPS Diluted -0.912.63-0.54-0.64-0.86-0.11-0.29-0.64-0.84-0.21-0.350.032-0.220.57-0.29-0.44-0.252.1-0.26-0.32-0.27-0.086-0.017-0.016-0.09-0.09
EBITDA -18.22160.637-11.701-11.512-15.801-2.837-4.662-13.468-11.762-6.954-5.872.01-7.0177.553-6.637-8.932-4.7084.24700-0.017-0.0010.001-0.001-0.718-0.718
EBITDA Ratio -21.9270.878-13.465-8.477-7.007-0.177-0.269-1.501-2.574-1.189-0.5890.126-1.8240.367-1.732-3.135-13.686108.89700000000